AI precision diagnostics for medical research
Open for applications
AI precision diagnostics for medical research
101-200 employees
Open for applications
101-200 employees
To help take drug research from visual estimations under a microscope to precise analysis and quantification.
Jump to section
To help take drug research from visual estimations under a microscope to precise analysis and quantification.
Few candidates hear
back within 2 weeks
47% employee growth in 12 months
There has been a worldwide increase in the numbers and complexity of cancer cases, alongside a predicted global shortage of pathologists. With this, classic manual analysis does not have the capability to support the precision medicine and drug development processes of the future.
Through its precision diagnostics platform, Aignostics turns complex biomedical data into transformative insights. It is able to power target identification (for drug development) and biomarker analyses, as well as support clinical trials with its toolkits.
The company plans to continue expanding its portfolio with new product offerings for biopharmaceutical clients. It is also leveraging its latest funding round to support growth in the US, as well as the development of leading foundation models for pathology in collaboration with Mayo Clinic.
Steph
Company Specialist at Welcome to the Jungle
Oct 2024
$34m
SERIES B
Sep 2022
$14.6m
SERIES A
Viktor Matyas
(Co-Founder & CEO)Experience as a Research Analyst at Arthur D Little, and Junior Engagement Manager at McKinsey.
Maximilian Alber
(Co-Founder & CTO)Previously Intern at Google and Researcher at the Berlin Institute of Technology.
Software Engineering
Data
Finance, Legal & Compliance
Design